Fusion-competent vaccines: Broad neutralization of primary isolates of HIV

Science

Volumn 283, Issue 5400, 1999, Pages 357-362

  LaCasse, Rachel A ^a   Follis, Kathryn E ^a   Trahey, Meg ^a   Scarborough, John D ^b,c   Littman, Dan R ^b   Nunberg, Jack H ^a  

^a UNIVERSITY OF MONTANA   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUSION COMPETENT HUMAN IMMUNODEFICIENCY VIRUS VACCINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; DRUG EFFICACY; GENE FUSION; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; VACCINATION; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANIMALS; ANTIGENS, CD4; CELL FUSION; COCULTURE TECHNIQUES; EPITOPES; GENE PRODUCTS, ENV; GIANT CELLS; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, TRANSGENIC; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; RECEPTORS, CCR5; TUMOR CELLS, CULTURED;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS MUSCULUS;

EID: 0033555453     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.283.5400.357     Document Type: Article

References (61)

1. UNAIDS Report (available at www.unaids.org/highband/ document/epidemio/wadr98e.pdf).
2. T. Wrin, T. P. Loh, J. Charron-Vennari, H. Schuitemaker, J. H. Nunberg, J. Virol. 69, 39 (1995).
3. J. P. Moore and D. D. Ho, AIDS 9 (suppl. A), S117 (1995); J. R. Mascola et al., J. Infect. Dis. 173, 340 (1996); R. I. Connor et al., J. Virol. 72, 1552 (1998); B. S. Graham et al., J. Infect. Dis. 177, 310 (1998).
4. J. P. Moore and D. D. Ho, AIDS 9 (suppl. A), S117 (1995); J. R. Mascola et al., J. Infect. Dis. 173, 340 (1996); R. I. Connor et al., J. Virol. 72, 1552 (1998); B. S. Graham et al., J. Infect. Dis. 177, 310 (1998).
5. J. P. Moore and D. D. Ho, AIDS 9 (suppl. A), S117 (1995); J. R. Mascola et al., J. Infect. Dis. 173, 340 (1996); R. I. Connor et al., J. Virol. 72, 1552 (1998); B. S. Graham et al., J. Infect. Dis. 177, 310 (1998).
6. J. P. Moore and D. D. Ho, AIDS 9 (suppl. A), S117 (1995); J. R. Mascola et al., J. Infect. Dis. 173, 340 (1996); R. I. Connor et al., J. Virol. 72, 1552 (1998); B. S. Graham et al., J. Infect. Dis. 177, 310 (1998).
7. R. B. Belshe et al., J. Am. Med. Assoc. 272, 475 (1994); J. O. Kahn et al., J. Infect. Dis. 170, 1288 (1994).
8. R. B. Belshe et al., J. Am. Med. Assoc. 272, 475 (1994); J. O. Kahn et al., J. Infect. Dis. 170, 1288 (1994).
9. J. Cohen, Science 262, 980 (1993); ibid. 264, 1839 (1994).
10. J. Cohen, Science 262, 980 (1993); ibid. 264, 1839 (1994).
11. J. R. Mascola et al., AIDS Res. Hum. Retrovir. 12, 13198 (1996); J. P. Moore et al., J. Virol. 70, 427 (1996); L. G. Kostrikis, Y. Cao, H. Ngai, J. P. Moore, D. D. Ho, ibid., p. 445; J. Weber, E. M. Fenyo, S. Beddows, P. Kaleebu, A. Bjorndal, ibid., p. 7827.
12. J. R. Mascola et al., AIDS Res. Hum. Retrovir. 12, 13198 (1996); J. P. Moore et al., J. Virol. 70, 427 (1996); L. G. Kostrikis, Y. Cao, H. Ngai, J. P. Moore, D. D. Ho, ibid., p. 445; J. Weber, E. M. Fenyo, S. Beddows, P. Kaleebu, A. Bjorndal, ibid., p. 7827.
13. J. R. Mascola et al., AIDS Res. Hum. Retrovir. 12, 13198 (1996); J. P. Moore et al., J. Virol. 70, 427 (1996); L. G. Kostrikis, Y. Cao, H. Ngai, J. P. Moore, D. D. Ho, ibid., p. 445; J. Weber, E. M. Fenyo, S. Beddows, P. Kaleebu, A. Bjorndal, ibid., p. 7827.
14. J. R. Mascola et al., AIDS Res. Hum. Retrovir. 12, 13198 (1996); J. P. Moore et al., J. Virol. 70, 427 (1996); L. G. Kostrikis, Y. Cao, H. Ngai, J. P. Moore, D. D. Ho, ibid., p. 445; J. Weber, E. M. Fenyo, S. Beddows, P. Kaleebu, A. Bjorndal, ibid., p. 7827.
15. Reviewed in E. A. Berger, AIDS 11 (suppl. A), S3 (1997); J. P. Moore, A. Trkola, T. Dragic, Curr. Opin. Immunol. 9, 551 (1997); B. J. Doranz, J. F. Berson, J. Rucker, R. W. Doms, Immunol. Res. 16, 15 (1997).
16. Reviewed in E. A. Berger, AIDS 11 (suppl. A), S3 (1997); J. P. Moore, A. Trkola, T. Dragic, Curr. Opin. Immunol. 9, 551 (1997); B. J. Doranz, J. F. Berson, J. Rucker, R. W. Doms, Immunol. Res. 16, 15 (1997).
17. Reviewed in E. A. Berger, AIDS 11 (suppl. A), S3 (1997); J. P. Moore, A. Trkola, T. Dragic, Curr. Opin. Immunol. 9, 551 (1997); B. J. Doranz, J. F. Berson, J. Rucker, R. W. Doms, Immunol. Res. 16, 15 (1997).
18. The molecularly cloned envelope gene of ACH168.10 was isolated by polymerase chain reaction with the pCR3.1-Uni plasmid (Invitrogen) [(2, 15); M. Tersmette et al., J. Virol. 63, 2118 (1989)].
19. 6 cells each) in 10-cm culture dishes. The time course of cell-cell fusion was monitored microscopically and by immunochemical staining (HIVIG) in parallel cocultures (15). Cocultures were harvested by formaldehyde fixation at 4 to 5 hours, when little or no overt syncytium formation was evident.
20. 6 cells each) in 10-cm culture dishes. The time course of cell-cell fusion was monitored microscopically and by immunochemical staining (HIVIG) in parallel cocultures (15). Cocultures were harvested by formaldehyde fixation at 4 to 5 hours, when little or no overt syncytium formation was evident.
21. 6 cells/0.1 ml in PBS containing 10% dimethyl sulfoxide, and frozen at -80°C.
22. 6 cells/0.1 ml in PBS containing 10% dimethyl sulfoxide, and frozen at -80°C.
23. J. D. Scarborough, W. Ellmeier, D. R. Littman, unpublished results. Construction of a CD4 targeted deletion and hu CD4 transgenic mouse has been described [N. Killeen, S. Sawada, D. R. Littman, EMBO J. 12, 1547 (1993)]. Briefly, a hu CCR5 transgenic mouse was constructed by molecularly cloning a 1.15-kb hu CCR5 cDNA into an engineered Sal 1 site in exon 2 of a murine CD4 expression cassette [construct c in S. Sawada, J. D. Scarborough, N. Killeen, D. R. Littman, Cell 77, 917 (1994)]. This minigene contains the murine CD4 enhancer, the CD4 promoter, the first (noncoding) exon, and intron 1 with an internal deletion that eliminates the CD4 silencer. Transgenic founders were identified by flow cytometry with a monoclonal antibody (mAb) to CCR5. These animals were bred to hu CD4 transgenic mice to yield progeny expressing hu CD4, hu CCR5, and mouse CD4. Pups were screened for expression of hu CD4, hu CCRS, and mouse CD4 by flow cytometry with a Coulter EPICS ELITE flow cytometer. The following antibody reagents were used: mouse antibody to human CD4 conjugated to CyChrome (Pharmingen). mouse antibody to human CCR5 mAb 180 (R&D Systems) with goat antibody to mouse immunoglobulin conjugated to fluorescein isothiocyanate (Caltag), and rat antibody to mouse CD4 L3T4 conjugated to phycoerythrin.
24. J. D. Scarborough, W. Ellmeier, D. R. Littman, unpublished results. Construction of a CD4 targeted deletion and hu CD4 transgenic mouse has been described [N. Killeen, S. Sawada, D. R. Littman, EMBO J. 12, 1547 (1993)]. Briefly, a hu CCR5 transgenic mouse was constructed by molecularly cloning a 1.15-kb hu CCR5 cDNA into an engineered Sal 1 site in exon 2 of a murine CD4 expression cassette [construct c in S. Sawada, J. D. Scarborough, N. Killeen, D. R. Littman, Cell 77, 917 (1994)]. This minigene contains the murine CD4 enhancer, the CD4 promoter, the first (noncoding) exon, and intron 1 with an internal deletion that eliminates the CD4 silencer. Transgenic founders were identified by flow cytometry with a monoclonal antibody (mAb) to CCR5. These animals were bred to hu CD4 transgenic mice to yield progeny expressing hu CD4, hu CCR5, and mouse CD4. Pups were screened for expression of hu CD4, hu CCRS, and mouse CD4 by flow cytometry with a Coulter EPICS ELITE flow cytometer. The following antibody reagents were used: mouse antibody to human CD4 conjugated to CyChrome (Pharmingen). mouse antibody to human CCR5 mAb 180 (R&D Systems) with goat antibody to mouse immunoglobulin conjugated to fluorescein isothiocyanate (Caltag), and rat antibody to mouse CD4 L3T4 conjugated to phycoerythrin.
25. J. D. Scarborough, W. Ellmeier, D. R. Littman, unpublished results. Construction of a CD4 targeted deletion and hu CD4 transgenic mouse has been described [N. Killeen, S. Sawada, D. R. Littman, EMBO J. 12, 1547 (1993)]. Briefly, a hu CCR5 transgenic mouse was constructed by molecularly cloning a 1.15-kb hu CCR5 cDNA into an engineered Sal 1 site in exon 2 of a murine CD4 expression cassette [construct c in S. Sawada, J. D. Scarborough, N. Killeen, D. R. Littman, Cell 77, 917 (1994)]. This minigene contains the murine CD4 enhancer, the CD4 promoter, the first (noncoding) exon, and intron 1 with an internal deletion that eliminates the CD4 silencer. Transgenic founders were identified by flow cytometry with a monoclonal antibody (mAb) to CCR5. These animals were bred to hu CD4 transgenic mice to yield progeny expressing hu CD4, hu CCR5, and mouse CD4. Pups were screened for expression of hu CD4, hu CCRS, and mouse CD4 by flow cytometry with a Coulter EPICS ELITE flow cytometer. The following antibody reagents were used: mouse antibody to human CD4 conjugated to CyChrome (Pharmingen). mouse antibody to human CCR5 mAb 180 (R&D Systems) with goat antibody to mouse immunoglobulin conjugated to fluorescein isothiocyanate (Caltag), and rat antibody to mouse CD4 L3T4 conjugated to phycoerythrin.
26. 6 cells/0.1 ml) formulated with an equal volume of Ribi adjuvant (R-700; reconstituted in half the recommended volume of PBS); in some experiments, the initial immunization was with adjuvant containing cell wall material (R-730). Mice received 0.05 ml of vaccine in four subcutaneous sites. Booster immunizations were at 3-week intervals, and mice were bled from the tail at 10 to 28 days after immunizations. Ultimately, mice were boosted and exsanguinated by cardiac puncture in order to obtain larger quantities of serum. Animal care was in accordance with institutional guidelines. Serum antibodies directed to gp120 were quantitated by gp120 enzyme-linked immunosorbent assay (ELISA) [J. Moore, L. Wallace, E. Follett, J. McKeating, AIDS 3, 155 (1989)].
27. This rapid PI virus neutralization assay has been validated relative to our standard neutralization assay in peripheral blood lymphocyte (PBL) culture (15, 17) and performs well in the presence of mouse serum. All sera were heat inactivated before use in neutralization assays.
28. R. A. LaCasse et al., data not shown. Serum was adsorbed sequentially to protein A Sepharose (Sigma) and protein G agarose (Sigma) at 4°C. Adsorption of antibody was confirmed by gp120 ELISA. The solid supports were combined and antibodies were eluted with 100 mM glycine, pH 2.5. The eluate was neutralized and dialyzed by centrifugal ultrafiltration (Microcon-100; Amicon).
29. R. A. LaCasse et al., J. Virol. 72, 2491 (1998).
30. A. Trkola et al., ibid., p. 1876; D. C. Montefiori et al., ibid., p. 3427.
31. A. Trkola et al., ibid., p. 1876; D. C. Montefiori et al., ibid., p. 3427.
32. K. E. Follis, M. Trahey, R. A. LaCasse, J. H. Nunberg, ibid., p. 7603.
33. Envelope-expressing cultures were incubated with sCD4 [E. A. Berger, T. R. Fuerst, B. Moss, Proc. Natl. Acad. Sci. U.S.A. 85, 2357 (1988)] (5 μg/ml; 1 hour at 37°C) and subsequently washed to remove unbound sCD4. All FI immunogens were fixed with formaldehyde as described in (10).
34. - provirus was pseudotyped with amphotropic MLV envelope protein [H. Deng et al., Nature 381, 661 (1996)].
35. A primary isolate of SIVmac251 [A. L. Langlois et al., J. Virol. 72, 6950 (1998)] was produced in rhesus PBLs.
36. A statistical comparison was performed on data comprising all experimental animals and all virus neutralization assays. A simple model for virus-antibody binding was used to calculate a "binding constant" K for each assay, and a mean K value was determined for each mouse. Two-sample unpooled t tests were performed on log-transformed K values to compare groups pairwise. Bonferroni-adjusted comparison demonstrated a significant difference in mean neutralization between FC and FI immunogens (P = 0.001). This analysis included 26 independent neutralization assays of FC sera, from all mice receiving FC immunogen, and similarly, 35 assays of FI sera. In all experiments, responses within experimental groups were consistent and uniform.
37. M. P. Cranage et al., AIDS Res. Hum. Retrovir. 9, 13 (1993); P. Putkonen et al., J. Med. Primatol. 22, 100 (1993); L. O. Arthur et al., Science 258, 1935 (1992).
38. M. P. Cranage et al., AIDS Res. Hum. Retrovir. 9, 13 (1993); P. Putkonen et al., J. Med. Primatol. 22, 100 (1993); L. O. Arthur et al., Science 258, 1935 (1992).
39. M. P. Cranage et al., AIDS Res. Hum. Retrovir. 9, 13 (1993); P. Putkonen et al., J. Med. Primatol. 22, 100 (1993); L. O. Arthur et al., Science 258, 1935 (1992).
40. Infectious proviruses ACH320.2A.1.2 (320SI) and ACH320.2A.2.1 (320NSI) [M. Groenink et al., J. Virol. 65, 1968 (1991); C. Guillon et al., AIDS Res. Hum. Retrovir. 11, 1537 (1995)] were obtained through the National Institute for Biological Standards and Controls (NIBSC, United Kingdom) AIDS Reagent Program from Hanneke Schuitemaker (Netherlands Red Cross). HIV89.6 [R. Collman et al., J. Virol. 66, 7517 (1992)], SHIV89.6, and SHIV89.6P [K. A. Reimann et al., ibid. 70, 3198 (1996)] were provided with permission by D. Montefiori (Duke University Medical Center). All other primary isolates were obtained through the NIH AIDS Research and Reference Reagent Program and the UNAIDS Network for HIV-1 Isolation and Characterization. PI viruses were subjected to limited expansion in phytohemagglutinin-activated PBLs (2).
41. Infectious proviruses ACH320.2A.1.2 (320SI) and ACH320.2A.2.1 (320NSI) [M. Groenink et al., J. Virol. 65, 1968 (1991); C. Guillon et al., AIDS Res. Hum. Retrovir. 11, 1537 (1995)] were obtained through the National Institute for Biological Standards and Controls (NIBSC, United Kingdom) AIDS Reagent Program from Hanneke Schuitemaker (Netherlands Red Cross). HIV89.6 [R. Collman et al., J. Virol. 66, 7517 (1992)], SHIV89.6, and SHIV89.6P [K. A. Reimann et al., ibid. 70, 3198 (1996)] were provided with permission by D. Montefiori (Duke University Medical Center). All other primary isolates were obtained through the NIH AIDS Research and Reference Reagent Program and the UNAIDS Network for HIV-1 Isolation and Characterization. PI viruses were subjected to limited expansion in phytohemagglutinin-activated PBLs (2).
42. Infectious proviruses ACH320.2A.1.2 (320SI) and ACH320.2A.2.1 (320NSI) [M. Groenink et al., J. Virol. 65, 1968 (1991); C. Guillon et al., AIDS Res. Hum. Retrovir. 11, 1537 (1995)] were obtained through the National Institute for Biological Standards and Controls (NIBSC, United Kingdom) AIDS Reagent Program from Hanneke Schuitemaker (Netherlands Red Cross). HIV89.6 [R. Collman et al., J. Virol. 66, 7517 (1992)], SHIV89.6, and SHIV89.6P [K. A. Reimann et al., ibid. 70, 3198 (1996)] were provided with permission by D. Montefiori (Duke University Medical Center). All other primary isolates were obtained through the NIH AIDS Research and Reference Reagent Program and the UNAIDS Network for HIV-1 Isolation and Characterization. PI viruses were subjected to limited expansion in phytohemagglutinin-activated PBLs (2).
43. Infectious proviruses ACH320.2A.1.2 (320SI) and ACH320.2A.2.1 (320NSI) [M. Groenink et al., J. Virol. 65, 1968 (1991); C. Guillon et al., AIDS Res. Hum. Retrovir. 11, 1537 (1995)] were obtained through the National Institute for Biological Standards and Controls (NIBSC, United Kingdom) AIDS Reagent Program from Hanneke Schuitemaker (Netherlands Red Cross). HIV89.6 [R. Collman et al., J. Virol. 66, 7517 (1992)], SHIV89.6, and SHIV89.6P [K. A. Reimann et al., ibid. 70, 3198 (1996)] were provided with permission by D. Montefiori (Duke University Medical Center). All other primary isolates were obtained through the NIH AIDS Research and Reference Reagent Program and the UNAIDS Network for HIV-1 Isolation and Characterization. PI viruses were subjected to limited expansion in phytohemagglutinin-activated PBLs (2).
44. M. Thali et al., J. Virol. 67, 3978 (1993); N. Sullivan et al., ibid. 72, 4694 (1998).
45. M. Thali et al., J. Virol. 67, 3978 (1993); N. Sullivan et al., ibid. 72, 4694 (1998).
46. J. M. Gershoni et al., FASEB J. 7, 1185 (1993); S. Lee et al., J. Virol. 71, 6037 (1997).
47. J. M. Gershoni et al., FASEB J. 7, 1185 (1993); S. Lee et al., J. Virol. 71, 6037 (1997).
48. 6 formaldehyde-fixed COS cells expressing 168P envelope protein. Incubations were for 1 hour at 4°C with rocking. Controls included prebleed serum and formaldehyde-fixed, mock-transfected COS cells. Adsorption of bulk anti-gp120 was monitored by gp120 ELISA. Final sera were tested for neutralization of HIV 168P with U87-CD4-CXCR4 cells. Parallel studies with intact but non-fixed cells yielded concordant results.
49. 4 cells per 96-well microculture) for 1 hour at 37°C with occasional mixing. Supernatants were tested for neutralization of HIV 168P with U87-CD4-CCR5 cells.
50. W. Weissenhorn et al., Nature 387, 426 (1997); D. C. Chan, D. Fass, J. M. Berger, P. S. Kim, Cell 89, 263 (1997); W. Weissenhorn, L. J. Calder, S. A. Wharton, J. J. Skehel, D. C. Wiley, Proc. Natl. Acad. Sci. U.S.A. 95, 6032 (1998).
51. W. Weissenhorn et al., Nature 387, 426 (1997); D. C. Chan, D. Fass, J. M. Berger, P. S. Kim, Cell 89, 263 (1997); W. Weissenhorn, L. J. Calder, S. A. Wharton, J. J. Skehel, D. C. Wiley, Proc. Natl. Acad. Sci. U.S.A. 95, 6032 (1998).
52. W. Weissenhorn et al., Nature 387, 426 (1997); D. C. Chan, D. Fass, J. M. Berger, P. S. Kim, Cell 89, 263 (1997); W. Weissenhorn, L. J. Calder, S. A. Wharton, J. J. Skehel, D. C. Wiley, Proc. Natl. Acad. Sci. U.S.A. 95, 6032 (1998).
53. C. Wild, T. Oas, C. McDanal, D. Bolognesi, T. Matthews, Proc. Natl. Acad. Sci. U.S.A. 89, 10537 (1992); R. A. Furuta, C. T. Wild, Y. Weng, C. D. Weiss, Nature Struct. Biol. 5, 276 (1998).
54. C. Wild, T. Oas, C. McDanal, D. Bolognesi, T. Matthews, Proc. Natl. Acad. Sci. U.S.A. 89, 10537 (1992); R. A. Furuta, C. T. Wild, Y. Weng, C. D. Weiss, Nature Struct. Biol. 5, 276 (1998).
55. M. P. D'Souza et al., J. Infect. Dis. 175, 1056 (1997).
56. A. M. Prince et al., AIDS Res. Hum. Retrovir. 7, 971 (1991);
57. E. A. Emini et al., Nature 355, 728 (1992);
58. A. J. Conley et al., J. Virol. 70, 6751 (1996);
59. M. C. Gauduin et al., Nature Med. 3, 1389 (1997).
60. R. M. Krause, N. J. Dimmock, D. M. Morens, J. Infect. Dis. 176, 549 (1997).
61. J.H.N. was supported by targeted research grant 02560-23-RGV from the American Foundation for AIDS Research (AmFAR), funded in part by Concerned Parents for AIDS Research (CPFA). Additional funds were provided by The University of Montana, NIH AREA grant AI41165, and the M. J. Murdock Charitable Trust. D.R.L. was supported by NIH grant AI33856 and by a grant from AmFAR and is an investigator of the Howard Hughes Medical Institute. We thank E. Walker (Ribi ImmunoChem Research, Incorporated, Hamilton, MT) and L. Griggs for flow cytometry, C. Mackay (Leukosite) and M. Tsang for CCR5 mAbs, W Ellmeier for the transgenic mouse CCR5 construct, D. Montefiori (Duke University Medical Center) for providing SIVmac251, HIV 89.6, and related SHIV viruses, and C. Weiss (U.S. Food and Drug Administration) for providing amphotropte MLV envelope protein pseudotyped HIV virions. Primary HIV isolates and other reagents were obtained from the NIH AIDS Research and Reference Reagent Program, the NIBSC (UK) AIDS Reagent Program, and the UNAIDS Network for HIV-1 Isolation and Characterization. We are grateful to D. A. Patterson (University of Montana, Department of Mathematics) for statistical analysis of neutralization data, and to J. Moore and D. Montefiori for constructive review of the manuscript Discussions with C Barbas III and E. Berger were important in the development of these studies.